Roche Holding AG (RHHBF)
OTCMKTS
· Delayed Price · Currency is USD
328.00
-11.00 (-3.24%)
May 27, 2025, 4:00 PM EDT
Roche Holding AG Employees
Roche Holding AG had 103,249 employees as of December 31, 2024. The number of employees decreased by 356 or -0.34% compared to the previous year.
Employees
103,249
Change (1Y)
-356
Growth (1Y)
-0.34%
Revenue / Employee
$666,883
Profits / Employee
$88,465
Market Cap
252.44B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 103,249 | -356 | -0.34% |
| Dec 31, 2023 | 103,605 | -8 | -0.01% |
| Dec 31, 2022 | 103,613 | 2,693 | 2.67% |
| Dec 31, 2021 | 100,920 | -545 | -0.54% |
| Dec 31, 2020 | 101,465 | 3,730 | 3.82% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Endo Inc. | 3,116 |
| Tian'an Technology Group | 8 |
| Elite Pharmaceuticals | 64 |
| Glass House Brands | 374 |
| CytoDyn | 9 |
| Northwest Biotherapeutics | 25 |
| Silence Therapeutics | 116 |
| American Oncology Network | 1,914 |
Roche Holding AG News
- 3 days ago - Roche moves antibiotic against superbug into Phase 3 of testing - Reuters
- 4 days ago - Roche extends trials of promising antibiotic against resistant superbug - Financial Times
- 6 days ago - Tandem to pay Roche $36M in patent dispute settlement - Seeking Alpha
- 6 days ago - Roche wins EU endorsement for metastatic breast cancer treatment - Seeking Alpha
- 6 days ago - CHMP recommends EU approval of Roche's Itovebi for PIK3CA-mutated, ER-positive, HER2-negative, advanced breast cancer - GlobeNewsWire
- 7 days ago - Roche announces new collaboration with Broad Clinical Labs to accelerate adoption of cutting-edge SBX sequencing technology - GlobeNewsWire
- 7 days ago - New two-year follow-up of Roche's Columvi extends overall survival in relapsed or refractory diffuse large B-cell lymphoma patients - GlobeNewsWire
- 7 days ago - New Two-year Follow-up of Genentech's Columvi Extends Overall Survival in Relapsed or Refractory Diffuse Large B-cell Lymphoma Patients - Business Wire